Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to accelerate the development of vaccine candidates against diarrheal diseases caused by Shigella and Enterotoxigenic Escherichia coli (ETEC). We plan to identify cases of laboratory-proven shigellosis and ETEC-associated diarrhea, to study humoral and cellular immune parameters following natural infections with Shigella and ETEC, and to compare the level of pre-existing local, humoral and cellular immune parameters in cases of shigellosis and ETEC-associated diarrhea and in matched controls.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT01638039
Study type Interventional
Source Hillel Yaffe Medical Center
Contact
Status Not yet recruiting
Phase N/A
Start date July 2012
Completion date July 2016

See also
  Status Clinical Trial Phase
Completed NCT02280044 - Efficacy of Rifaximin in Preventing Campylobacteriosis Phase 2/Phase 3
Completed NCT01080716 - Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate Phase 1/Phase 2
Completed NCT00490932 - New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Diarrhea Management– Surveillance Study for Adverse Effects Phase 4
Completed NCT01306383 - Solar Disinfection (SODIS) of Drinking Water for Use in Developing Countries or in Emergency Situations N/A
Completed NCT03561181 - Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months Phase 1
Completed NCT04865497 - Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 3 Months to 5 Years Old Phase 2
Recruiting NCT05156528 - Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years Phase 3
Completed NCT01672580 - Social Network Interventions in Rural Honduras N/A